US Tariff Hike May Squeeze Indian Pharma Margins: Analysts

New Delhi, Aug 5 (KNN) The recent decision by the United States to impose a 25% tariff on certain Chinese-made pharmaceutical ingredients could indirectly impact Indian pharmaceutical companies, according to industry analysts.

Even though Indian companies largely depend on Chinese imports for active pharmaceutical ingredients (APIs), the ability to pass on higher costs to customers may not fully shield them from margin pressures.

Indian pharma firms source over 60% of their bulk drug needs from China. While the new US tariff does not directly target Indian exports, it may disrupt the global supply chain and increase input costs.

Companies might try to transfer these rising expenses to customers, but analysts say the margin impact could still be noticeable.

Experts also believe that the price-sensitive nature of the US generics market might make it difficult for Indian companies to increase prices without affecting their market share.

Additionally, with US regulators already closely monitoring the quality and compliance of Indian drug manufacturing units, firms might face further cost burdens to maintain their standing in the market.

The move is part of a broader US-China trade tension, and while it could present an opportunity for India to boost domestic API production, short-term challenges around cost, infrastructure, and technology remain.

Indian pharma players like Sun Pharma, Cipla, and Dr. Reddy’s may need to re-evaluate their procurement strategies and focus more on domestic manufacturing to mitigate the long-term impact.

Government support through schemes like the Production Linked Incentive (PLI) for APIs could help reduce dependency on Chinese imports over time.

In summary, while the full impact of the US tariffs is yet to unfold, the Indian pharmaceutical industry could face a squeeze in profit margins unless proactive measures are taken.

(KNN Bureau)